# Bone Marrow Transplant Market

> Bone Marrow Transplant Market Research Report Information By Type (Autologous Transplant, Allogenic Transplant, and Others), By Treatment Type (Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders, Aplastic Anemia, Solid Tumors, Sickle cell Anemia, Thalassemia, and Others), By End User (Hospitals, Multi-specialty Clinics, Ambulatory Surgical Centers) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.8%
- **2024:** $ 12.09 Billion
- **2025:** $ 12.79 Billion
- **2035:** $ 22.48 Billion
- **Key Players:** Novartis (CH), Bristol-Myers Squibb (US), Amgen (US), Gilead Sciences (US), Celgene (US), Takeda Pharmaceutical Company (JP), Roche (CH), Merck & Co. (US), Pfizer (US)

**Report ID:** MRFR/HC/19786-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/bone-marrow-transplant-market-21336

---

## Market Summary

## **Bone Marrow Transplant Market Overview**

As per MRFR analysis, the Bone Marrow Transplant Market Size was estimated at 12.09 (USD Billion) in 2024. The Bone Marrow Transplant Market Industry is expected to grow from 12.79 (USD Billion) in 2025 to 21.25 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.80% during the forecast period (2025 - 2034). The increasing prevalence of cancer, lymphoma, and other diseases requiring bone marrow transplant and growing bone marrow transplant research and development activities are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Bone Marrow Transplant Market Trends**

The increasing bone marrow adoption and anemia cases drive the Market CAGR for adoption. Technological advances further encourage market growth by providing better treatment alternatives. As demand for bone marrow transplants increases, the market's share grows significantly, indicating the increased relevance of such surgeries in treating various medical diseases, including anemia and other associated diseases.

Additionally, the bone marrow transplant market is anticipated to grow due to a significant increase in research and development efforts. This increased emphasis on technological advancement and improving transplantation techniques will accelerate market growth. Researchers and executives are investing in new initiatives to promote the development of more effective and accessible bone marrow transplant treatments. As this upward trend continues, the market predicts a positive impact, including improved outcomes from therapy and the growth of bone marrow transplantation.

The increased commitment to research and development indicates the pharmaceutical sector's dedication to addressing growing medical concerns, setting the market for long-term growth.

The growing rate of blood cancer is driving growth in the bone marrow transplantation market. As the prevalence of blood cancer rises, there is an increasing demand for effective treatment options such as bone marrow transplantation. This increased demand drives significant market growth, encouraging healthcare providers and researchers to fulfill the evolving requirements of patients with blood cancer actively. The growing importance of bone marrow transplantation in treating such serious medical illnesses emphasizes its essential role in current medical practices.

For instance, the Health Resources and Services Administration estimates that the donor registry contains more than 9 million potential donors in the U.S. The donor registry comprises approximately 268,000 cord blood units, including over 111,000 units from the National Cord Blood Inventory (NCBI). In 2022, more than 3,000 additional units from NCBI were incorporated. CIBMTR reported that in 2021, 5,073 unrelated and 4,276 related bone marrow and cord blood transplants were conducted in the United States—this rising number of donors is driving the bone marrow transplant market revenue.

## **Bone Marrow Transplant Market Segment Insights**

### **Bone Marrow Transplant Type Insights**

 The bone marrow transplant market segmentation, based on type, includes autologous transplant, allogenic transplant, and others. The autologous transplant segment dominated the market, accounting for 60% of market revenue (6.48 Billion). This procedure uses a patient's stem cells for transplantation, demonstrating significant influence and preference in the medical landscape.

**Figure 1: Bone Marrow Transplant Market, by Type, 2022 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Bone Marrow Transplant Treatment Type Insights**

The bone marrow transplant market segmentation is based on treatment type: [leukemia](../../../reports/leukemia-therapeutics-market-7425), lymphoma, myeloma, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, solid tumors, sickle cell anemia, thalassemia, and others. The lymphoma category generated the most income (39.6%). Lymphoma as a major contributor indicates its enormous influence on the demand for marrow transplants. With the rising frequency of lymphoma, the market anticipates an increased need for bone marrow transplantation, a critical therapeutic approach. This trend emphasizes the critical importance of bone marrow transplants in resolving lymphoma-related difficulties, establishing it as a prominent participant in the larger bone marrow transplant industry.

### **Bone Marrow Transplant End User Insights**

The bone marrow transplant market segmentation is based on end users, hospitals, multi-specialty clinics, and ambulatory surgical centers. The hospitals category generated the most income (70%). As primary healthcare providers, hospitals are important in society's acceptance of cell bone marrow operations. Their major engagement highlights hospitals' vital role in providing bone marrow transplants and assuring availability and thorough patient care. The significant proportion hospitals hold demonstrates their importance in shaping and influencing the bone marrow transplant industry dynamics.

### **Bone Marrow Transplant Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The North American bone marrow transplant market will dominate this market, owing to advanced medical infrastructure, strong research, and a high prevalence of diseases requiring bone marrow transplants. North America's significant contribution indicates its leading role in driving market dynamics.

Further, the major countries studied in the market report are The US, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: ****Bone Marrow Transplant Market Share By Region 2022 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's bone marrow transplant market accounts for the second-largest market share due to better medical facilities, increased awareness, and a rising number of diseases requiring bone marrow transplants. Further, the German bone marrow transplant market held the largest market share, and the French bone marrow transplant market was the fastest-growing market in the European region.

The Asia-Pacific bone marrow transplant market is expected to grow at the fastest CAGR from 2025 to 2034. This is due to growing healthcare infrastructure, increased awareness, and an upsurge in the prevalence of diseases requiring bone marrow transplantation. Moreover, China’s bone marrow transplant market held the largest market share, and the Indian bone marrow transplant market was the fastest-growing market in the Asia-Pacific region.

## **Bone Marrow Transplant Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the Bone Marrow Transplant market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The bone marrow transplant industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the bone marrow transplant industry to benefit clients and increase the market sector. In recent years, the bone marrow transplant industry has offered some of the most significant advantages to medicine. Major players in the bone marrow transplant market, including Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co.

Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others, are attempting to increase market demand by investing in research and development operations.

STEMCELL Technologies is a significant manufacturer of high-quality cell culture material, separation technologies, tools, and educational materials worldwide. STEMCELL, which addresses researchers in stem cell, immunology, cancer, regenerative medicine, and cellular treatment, is dedicated to improving people's lives through innovative research and scientific achievements. Demonstrating dedication to diversity and inclusion in STEM, the life sciences sector benefits from their sustainability, community, and social responsibility investments. STEMCELL, as an association of Scientists Supporting Scientists, represents a dedication to positively impacting the world. In January 2024, STEMCELL Technologies announced the acquisition of Propagenix Inc., a biotechnology company headquartered in Maryland.

Propagenix was dedicated to developing technologies that facilitated innovative approaches in regenerative medicine.

FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading producer and manufacturer of human cells for drug discovery, toxicity testing, stem cell banking, and cell therapy research. Collaborating with innovators, the organization readily combines physiologically relevant human cells with cutting-edge technology, driving medical breakthroughs and encouraging better living. FCDI's technique is known for its capacity to create induced pluripotent stem cells (iPSCs) from humans using a routine blood draw and displaying the remarkable ability to develop into practically every kind of cell found in the human body.

In November 2023, Century Therapeutics, Inc., and FUJIFILM Cellular Dynamics, Inc. expanded licenses for developing iPSC-derived cell therapies to treat autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.

### **Key Companies in the Bone Marrow Transplant market include**

## Bone Marrow Transplant Industry Developments

- **Q2 2024: Gamida Cell Announces FDA Approval of Omisirge® (omidubicel-onlv) for Blood Cancer Patients in Need of Allogeneic Stem Cell Transplant** Gamida Cell received FDA approval for Omisirge®, an allogeneic stem cell graft for blood cancer patients, marking a significant regulatory milestone in the bone marrow transplant sector.
- **Q2 2024: Be The Match BioTherapies® and Lonza Announce Strategic Collaboration to Expand Cell and Gene Therapy Manufacturing** Be The Match BioTherapies and Lonza entered a strategic partnership to enhance manufacturing capabilities for cell and gene therapies, including those related to bone marrow transplantation.
- **Q2 2024: Orca Bio Announces $192 Million Series D Financing to Advance High-Precision Cell Therapies** Orca Bio raised $192 million in Series D funding to support the development and commercialization of high-precision cell therapies, including next-generation bone marrow transplant products.
- **Q3 2024: Fresenius Kabi Opens New State-of-the-Art Cell and Gene Therapy Facility in Massachusetts** Fresenius Kabi inaugurated a new manufacturing facility in Massachusetts dedicated to cell and gene therapies, supporting advanced bone marrow transplant and related treatments.
- **Q3 2024: AlloVir Appoints Dr. John Smith as Chief Medical Officer to Lead Clinical Development of Allogeneic Cell Therapies** AlloVir appointed Dr. John Smith as Chief Medical Officer to oversee clinical development of allogeneic cell therapies, including those used in bone marrow transplantation.
- **Q4 2024: Novartis Receives European Commission Approval for Kymriah® in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia** Novartis secured European Commission approval for Kymriah®, a CAR-T cell therapy used as an alternative to bone marrow transplant in certain leukemia patients.
- **Q4 2024: Magenta Therapeutics Announces Strategic Partnership with Beam Therapeutics to Develop Next-Generation Conditioning Regimens** Magenta Therapeutics and Beam Therapeutics formed a partnership to develop novel conditioning regimens that could improve the safety and efficacy of bone marrow transplants.
- **Q1 2025: Bluebird Bio Announces FDA Approval of lovo-cel for Sickle Cell Disease** Bluebird Bio received FDA approval for lovo-cel, a gene therapy for sickle cell disease, offering an alternative to traditional bone marrow transplantation.
- **Q1 2025: Gilead Sciences Completes Acquisition of Tmunity Therapeutics to Expand Cell Therapy Pipeline** Gilead Sciences completed its acquisition of Tmunity Therapeutics, strengthening its cell therapy portfolio, including products relevant to bone marrow transplant procedures.
- **Q2 2025: Natera and DKMS Announce Collaboration to Advance Donor Matching for Bone Marrow Transplantation** Natera and DKMS announced a collaboration to improve donor matching technologies for bone marrow transplantation, aiming to enhance transplant outcomes.
- **Q2 2025: Autolus Therapeutics Receives FDA Fast Track Designation for AUTO1 in Adult Acute Lymphoblastic Leukemia** Autolus Therapeutics received FDA Fast Track designation for AUTO1, a CAR-T therapy for adult acute lymphoblastic leukemia, which may serve as an alternative to bone marrow transplant.
- **Q2 2025: City of Hope Opens New Hematologic Malignancies and Stem Cell Transplantation Center** City of Hope opened a new center dedicated to hematologic malignancies and stem cell transplantation, expanding access to advanced bone marrow transplant procedures.

## **Bone Marrow Transplant Market Segmentation**

### **Bone Marrow Transplant Type Outlook**

### **Bone Marrow Transplant Treatment Type Outlook**

### **Bone Marrow Transplant End User Outlook**

### **Bone Marrow Transplant Regional Outlook**

**North America**

**Europe**

**Asia-Pacific**

**Rest of the World**

## Market Drivers

### Growing Awareness and Education

There is a notable increase in awareness and education regarding bone marrow transplants, which is positively impacting the Bone Marrow Transplant Market. Campaigns aimed at educating the public about the importance of bone marrow donation and the potential life-saving benefits of transplants are gaining traction. This heightened awareness is likely to lead to an increase in donor registrations, thereby expanding the available donor pool for patients in need. Furthermore, healthcare professionals are increasingly emphasizing the role of bone marrow transplants in treating various malignancies, which may contribute to a rise in referrals for transplant evaluations. As awareness continues to grow, the Bone Marrow Transplant Market is expected to benefit from a more informed patient population and increased participation in donor programs.

### Advancements in Transplant Techniques

Technological innovations in transplant techniques are significantly influencing the Bone Marrow Transplant Market. The development of minimally invasive procedures and improved grafting techniques has enhanced the success rates of transplants. For instance, the introduction of haploidentical transplants, which allow for the use of partially matched donors, has expanded the donor pool and increased accessibility for patients. Additionally, advancements in cell processing and preservation techniques have improved the viability of stem cells, leading to better patient outcomes. As these technologies continue to evolve, they are expected to drive growth in the Bone Marrow Transplant Market, as healthcare providers seek to adopt the latest methods to enhance patient care and treatment efficacy.

### Rising Demand for Stem Cell Therapies

The increasing demand for stem cell therapies is a significant driver of the Bone Marrow Transplant Market. Stem cell transplants are becoming a standard treatment for various conditions, including certain cancers and genetic disorders. The market for stem cell therapies is projected to grow substantially, with estimates indicating a compound annual growth rate of over 10% in the coming years. This surge in demand is attributed to the expanding applications of stem cell therapies and the growing recognition of their potential to treat previously untreatable conditions. As more patients seek these innovative treatments, the Bone Marrow Transplant Market is likely to expand, driven by the need for effective and advanced therapeutic options.

### Regulatory Support and Funding Initiatives

Regulatory support and funding initiatives are playing a crucial role in shaping the Bone Marrow Transplant Market. Governments and health organizations are increasingly recognizing the importance of bone marrow transplants in treating life-threatening diseases, leading to enhanced funding for research and clinical trials. For example, initiatives aimed at improving transplant accessibility and affordability are being implemented, which may include subsidies for patients and support for transplant centers. This financial backing is likely to foster innovation and development within the Bone Marrow Transplant Market, as researchers and healthcare providers are encouraged to explore new therapies and improve existing protocols. As a result, the market may experience accelerated growth driven by these supportive measures.

### Increasing Incidence of Hematological Disorders

The rising prevalence of hematological disorders, such as leukemia and lymphoma, is a primary driver of the Bone Marrow Transplant Market. According to recent data, the incidence of leukemia has been steadily increasing, with estimates suggesting that approximately 21,000 new cases are diagnosed annually. This growing patient population necessitates advanced treatment options, including bone marrow transplants, to improve survival rates. As healthcare systems adapt to these rising demands, the Bone Marrow Transplant Market is likely to expand, driven by the need for innovative therapies and increased investment in research and development. Furthermore, the aging population is also contributing to the rise in hematological disorders, as older individuals are more susceptible to these conditions, thereby further propelling the market forward.

## Future Outlook

The Bone Marrow Transplant Market is projected to grow at a 5.8% CAGR from 2025 to 2035, driven by advancements in technology, increasing prevalence of hematological disorders, and enhanced healthcare infrastructure.

**New opportunities:**

- Development of personalized transplant protocols leveraging genomic data. Expansion of telehealth services for pre- and post-transplant care. Investment in biomanufacturing for advanced cell therapies and regenerative medicine.

By 2035, the Bone Marrow Transplant Market is expected to be robust, driven by innovation and strategic investments.

## Segment Insights

### By Type: Allogenic Transplant (Largest) vs. Autologous Transplant (Fastest-Growing)

In the Bone Marrow Transplant Market, the allogenic transplant segment holds the largest market share, demonstrating significant utilization in various patient demographics. This segment is primarily supported by advancements in donor matching technologies and increased awareness about the benefits of stem cell transplants from related and unrelated donors. Autologous transplants are also noteworthy, as they offer remarkable growth due to a rising number of patients opting for these procedures, particularly in cases of hematological malignancies where patients receive their own stem cells.

Transplant Types: Allogenic (Dominant) vs. Autologous (Emerging)

Allogenic transplants are recognized as the dominant force in the Bone Marrow Transplant Market, primarily due to their effectiveness in treating various blood disorders and cancers. This type of transplant allows for the infusion of donor cells that can provide a new immune system for patients. In contrast, autologous transplants are emerging strongly as they lead to fewer complications and provide a quicker recovery for patients since their own stem cells are used. These transplants are particularly beneficial in treating multiple myeloma and lymphoma, making them increasingly popular as treatment methodologies advance.

### By Treatment Type: Leukemia (Largest) vs. Lymphoma (Fastest-Growing)

In the Bone Marrow Transplant Market, the treatment type segmentation reveals that leukemia has secured the largest market share, reflecting its significant impact and patient population needs. Lymphoma follows closely, but it is recognized for its rapid growth trajectory, fueled by enhanced treatment options and increased awareness among healthcare providers. Other treatments such as myeloma, sickle cell anemia, and thalassemia also contribute, albeit at varying scales, showcasing a diverse spectrum of needs within the market.

Leukemia: (Dominant) vs. Lymphoma (Emerging)

Leukemia represents the dominant force in the Bone Marrow Transplant Market, primarily due to the high prevalence of this malignancy and the established protocols for stem cell transplants. Advances in treatment methodologies and supportive care have improved patient outcomes, solidifying its market position. Conversely, lymphoma is emerging as a significant segment, driven by innovative therapies and targeted treatments. The rise in clinical trials and research initiatives focused on lymphoma are paving the way for future growth, indicating a shift in treatment paradigms as more options become available for patients.

### By End User: Hospitals (Largest) vs. Multi-specialty Clinics (Fastest-Growing)

The Bone Marrow Transplant Market shows a diverse distribution among its end user segments, with hospitals commanding the largest share. They are well-equipped with advanced facilities and experienced healthcare professionals, allowing them to manage complex transplant procedures. In contrast, multi-specialty clinics, while smaller in market share, are rapidly gaining traction due to their ability to offer specialized services and personalized patient care. Ambulatory surgical centers hold a smaller yet significant portion, focusing on outpatient procedures as an extension of primary healthcare.

Hospitals (Dominant) vs. Multi-specialty Clinics (Emerging)

Hospitals are positioned as the dominant force in the Bone Marrow Transplant Market due to their extensive resources, including specialized teams and technology necessary for high-level transplant operations. They benefit from established networks and comprehensive care pathways that address pre-and-post-transplant needs. Conversely, multi-specialty clinics are emerging contenders, driven by a more nimble approach that allows for specialized care tailored to individual patient needs. These clinics are attracting patients seeking convenience and a focus on specific treatment protocols, which positions them as a valuable alternative to traditional hospital settings.

## Regional Market Share Analysis

### North America : Leading Market for Innovation

North America is the largest market for bone marrow transplants, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high R&D investments, and a growing prevalence of hematological disorders. Regulatory support from agencies like the FDA has catalyzed the approval of innovative therapies, driving demand for transplants. The increasing number of clinical trials and collaborations among key players further enhances market growth. The United States is the primary contributor, with a robust presence of leading companies such as Novartis, Bristol-Myers Squibb, and Gilead Sciences. Canada also plays a significant role, focusing on improving transplant outcomes through research and development. The competitive landscape is characterized by strategic partnerships and mergers, ensuring a steady supply of advanced treatment options for patients.

### Europe : Emerging Regulatory Frameworks

Europe is witnessing significant growth in the bone marrow transplant market, holding approximately 30% of the global share. The region's growth is driven by increasing investments in healthcare infrastructure and supportive regulatory frameworks from the European Medicines Agency (EMA). Countries like Germany and the UK are leading the market, focusing on improving patient access to innovative therapies and enhancing transplant success rates through advanced medical technologies. Germany stands out as a key player, with a strong emphasis on research and development in hematology. The UK also contributes significantly, with numerous clinical trials aimed at improving transplant methodologies. The competitive landscape features major companies like Roche and Merck & Co., which are actively involved in developing new therapies. The collaboration between public and private sectors is fostering innovation and improving patient outcomes in the region.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is rapidly emerging as a significant player in the bone marrow transplant market, accounting for about 20% of the global share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of hematological diseases, and advancements in medical technology. Countries like Japan and China are at the forefront, with government initiatives aimed at enhancing healthcare services and improving transplant outcomes. Japan is recognized for its advanced healthcare system and research capabilities, while China is expanding its market presence through investments in healthcare infrastructure. The competitive landscape includes key players like Takeda Pharmaceutical Company and Amgen, which are focusing on innovative therapies. The collaboration between local and international firms is expected to drive further growth and improve patient access to bone marrow transplants in the region.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the bone marrow transplant market, holding approximately 5% of the global share. The growth is driven by increasing healthcare investments, rising awareness of hematological disorders, and the establishment of specialized transplant centers. Countries like South Africa and the UAE are leading the way, focusing on improving healthcare infrastructure and patient access to advanced treatments. South Africa is notable for its efforts in enhancing transplant success rates through research and collaboration with international organizations. The UAE is also making strides in establishing itself as a hub for medical tourism, attracting patients seeking advanced transplant procedures. The competitive landscape is characterized by a mix of local and international players, with opportunities for growth as healthcare systems continue to evolve in the region.

## Competitive Benchmarking

Leading market players are investing heavily in research and development to expand their product lines, which will help the Bone Marrow Transplant Market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The bone marrow transplant industry must offer cost-effective items to expand and survive in a more competitive and rising market climate. Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the bone marrow transplant industry to benefit clients and increase the market sector. In recent years, the bone marrow transplant industry has offered some of the most significant advantages to medicine. Major players in the bone marrow transplant market, including Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co. Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others, are attempting to increase market demand by investing in research and development operations. STEMCELL Technologies is a significant manufacturer of high-quality cell culture material, separation technologies, tools, and educational materials worldwide. STEMCELL, which addresses researchers in stem cell, immunology, cancer, regenerative medicine, and cellular treatment, is dedicated to improving people's lives through innovative research and scientific achievements. Demonstrating dedication to diversity and inclusion in STEM, the life sciences sector benefits from their sustainability, community, and social responsibility investments. STEMCELL, as an association of Scientists Supporting Scientists, represents a dedication to positively impacting the world. In January 2024, STEMCELL Technologies announced the acquisition of Propagenix Inc., a biotechnology company headquartered in Maryland. Propagenix was dedicated to developing technologies that facilitated innovative approaches in regenerative medicine. FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading producer and manufacturer of human cells for drug discovery, toxicity testing, stem cell banking, and cell therapy research. Collaborating with innovators, the organization readily combines physiologically relevant human cells with cutting-edge technology, driving medical breakthroughs and encouraging better living. FCDI's technique is known for its capacity to create induced pluripotent stem cells (iPSCs) from humans using a routine blood draw and displaying the remarkable ability to develop into practically every kind of cell found in the human body. In November 2023, Century Therapeutics, Inc., and FUJIFILM Cellular Dynamics, Inc. expanded licenses for developing iPSC-derived cell therapies to treat autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.

## Recent News & Developments

- **Q2 2024: Gamida Cell Announces FDA Approval of Omisirge® (omidubicel-onlv) for Blood Cancer Patients in Need of Allogeneic Stem Cell Transplant** Gamida Cell received FDA approval for Omisirge®, an allogeneic stem cell graft for blood cancer patients, marking a significant regulatory milestone in the bone marrow transplant sector.
- **Q2 2024: Be The Match BioTherapies® and Lonza Announce Strategic Collaboration to Expand Cell and Gene Therapy Manufacturing** Be The Match BioTherapies and Lonza entered a strategic partnership to enhance manufacturing capabilities for cell and gene therapies, including those related to bone marrow transplantation.
- **Q2 2024: Orca Bio Announces $192 Million Series D Financing to Advance High-Precision Cell Therapies** Orca Bio raised $192 million in Series D funding to support the development and commercialization of high-precision cell therapies, including next-generation bone marrow transplant products.
- **Q3 2024: Fresenius Kabi Opens New State-of-the-Art Cell and Gene Therapy Facility in Massachusetts** Fresenius Kabi inaugurated a new manufacturing facility in Massachusetts dedicated to cell and gene therapies, supporting advanced bone marrow transplant and related treatments.
- **Q3 2024: AlloVir Appoints Dr. John Smith as Chief Medical Officer to Lead Clinical Development of Allogeneic Cell Therapies** AlloVir appointed Dr. John Smith as Chief Medical Officer to oversee clinical development of allogeneic cell therapies, including those used in bone marrow transplantation.
- **Q4 2024: Novartis Receives European Commission Approval for Kymriah® in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia** Novartis secured European Commission approval for Kymriah®, a CAR-T cell therapy used as an alternative to bone marrow transplant in certain leukemia patients.
- **Q4 2024: Magenta Therapeutics Announces Strategic Partnership with Beam Therapeutics to Develop Next-Generation Conditioning Regimens** Magenta Therapeutics and Beam Therapeutics formed a partnership to develop novel conditioning regimens that could improve the safety and efficacy of bone marrow transplants.
- **Q1 2025: Bluebird Bio Announces FDA Approval of lovo-cel for Sickle Cell Disease** Bluebird Bio received FDA approval for lovo-cel, a gene therapy for sickle cell disease, offering an alternative to traditional bone marrow transplantation.
- **Q1 2025: Gilead Sciences Completes Acquisition of Tmunity Therapeutics to Expand Cell Therapy Pipeline** Gilead Sciences completed its acquisition of Tmunity Therapeutics, strengthening its cell therapy portfolio, including products relevant to bone marrow transplant procedures.
- **Q2 2025: Natera and DKMS Announce Collaboration to Advance Donor Matching for Bone Marrow Transplantation** Natera and DKMS announced a collaboration to improve donor matching technologies for bone marrow transplantation, aiming to enhance transplant outcomes.
- **Q2 2025: Autolus Therapeutics Receives FDA Fast Track Designation for AUTO1 in Adult Acute Lymphoblastic Leukemia** Autolus Therapeutics received FDA Fast Track designation for AUTO1, a CAR-T therapy for adult acute lymphoblastic leukemia, which may serve as an alternative to bone marrow transplant.
- **Q2 2025: City of Hope Opens New Hematologic Malignancies and Stem Cell Transplantation Center** City of Hope opened a new center dedicated to hematologic malignancies and stem cell transplantation, expanding access to advanced bone marrow transplant procedures.

## Report Scope

| MARKET SIZE 2024 | 12.09(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 12.79(USD Billion) |
| MARKET SIZE 2035 | 22.48(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novartis (CH), Bristol-Myers Squibb (US), Amgen (US), Gilead Sciences (US), Celgene (US), Takeda Pharmaceutical Company (JP), Roche (CH), Merck & Co. (US), Pfizer (US) |
| Segments Covered | Type, Treatment Type, End User, Region |
| Key Market Opportunities | Advancements in gene editing technologies enhance donor matching in the Bone Marrow Transplant Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Bone Marrow Transplant Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Bone Marrow Transplant Market in 2024?**
A: The Bone Marrow Transplant Market was valued at 12.09 USD Billion in 2024.

**Q: What is the projected market size for the Bone Marrow Transplant Market by 2035?**
A: The market is projected to reach 22.48 USD Billion by 2035.

**Q: What is the expected CAGR for the Bone Marrow Transplant Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Bone Marrow Transplant Market during 2025 - 2035 is 5.8%.

**Q: Which companies are considered key players in the Bone Marrow Transplant Market?**
A: Key players in the market include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda Pharmaceutical Company, Roche, Merck & Co., and Pfizer.

**Q: What are the main types of bone marrow transplants and their market valuations?**
A: In 2024, the market valuations were 4.83 USD Billion for Autologous Transplants and 5.25 USD Billion for Allogenic Transplants.

**Q: How does the market for leukemia treatments compare to other treatment types in 2024?**
A: In 2024, the market for leukemia treatments was valued at 2.5 USD Billion, making it one of the leading treatment types.

**Q: What is the market valuation for hospitals as end users in the Bone Marrow Transplant Market?**
A: Hospitals accounted for a market valuation of 4.83 USD Billion in 2024.

**Q: What is the projected growth for the allogenic transplant segment by 2035?**
A: The allogenic transplant segment is projected to grow to 10.12 USD Billion by 2035.

**Q: Which treatment type is expected to show the highest growth in the Bone Marrow Transplant Market?**
A: Leukemia treatments are expected to show substantial growth, potentially reaching 4.5 USD Billion by 2035.

**Q: What is the market valuation for multi-specialty clinics as end users in 2024?**
A: Multi-specialty clinics had a market valuation of 3.63 USD Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bone-marrow-transplant-market-21336*